

Remarks***I. Status of the Claims***

Upon entry of the foregoing amendment, claims 1, 2, 37, 38 and 53 are pending in the application, with claims 1, 37 and 53 being the independent claims. Claims 3-36, 39-52 and 54-94 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein. These changes are believed to introduce no new matter, and their entry is respectfully requested.

II. Support for Claim Amendments

Applicants have amended claims 1 and 37 such that the full, un-abbreviated designations corresponding to the abbreviations found within these claims are recited at the first instance when these terms appear. Support for these claim amendments can be found throughout the specification. Specifically, support for the expression "tetraethylenediamine (TETA)," as recited in claim 1, can be found, *inter alia*, in the specification at page 117, lines 8-9. Support for the expression "N,N,N',N'-tetrakis[2-pyridyl-methyl]ethylenediamine (TPEN)," as recited in claim 1, can be found, *inter alia*, in the specification at page 53, lines 2-4. Support for the expression "Abeta peptide (A β)," as recited in claim 1, can be found, *inter alia*, in the specification at page 1, lines 16-19 and at page 24, lines 7-12. Support for the expression "reactive oxygen species (ROS)," as recited in claim 37, can be found, *inter alia*, in the specification at page 25, lines 21-22.


- 4 -

BUSH *et al.*
Appl. No. 09/380,704*Conclusion*

It is believed that the present application is in condition for immediate examination. Early notice to this effect is earnestly solicited. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

Date: 5/17/02

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made***In the Claims:***

Please cancel claims 3-36, 39-52 and 54-94 without prejudice or disclaimer.

Please amend claims 1 and 37 as follows:

1. A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of (a) a metal chelator selected from the group consisting of: bathocuproine, bathophenanthroline, penacillamine, [TETA] tetraethylenediamine (TETA), [TPEN] N,N,N',N'-tetrakis[2-pyridyl-methyl]ethylenediamine (TPEN) or hydrophobic derivatives thereof; and (b) one or more pharmaceutically acceptable carriers or diluents; for a time and under conditions to bring about said treatment; and

wherein said chelator reduces, inhibits or otherwise interferes with [A β] Abeta peptide (A β)-mediated production of radical oxygen species.

37. A pharmaceutical composition for treatment of conditions caused by amyloidosis, A β -mediated [ROS] reactive oxygen species (ROS) formation, or both, comprising: (a) a metal chelator selected from the group consisting of: bathocuproine, bathophenanthroline, penacillamine, TETA, and TPEN, or hydrophobic derivatives thereof; and (b) one or more pharmaceutically acceptable carriers or diluents.